AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26190629 — intervention group
Group type: EXPERIMENTAL
Intervention: AP (aiming point) measurements
Number of subjects: 100
Study 26190629 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of demographic and anatomic parameters
Number of subjects: 100
Study 24176448 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDP > 22 mm Hg
Number of subjects: 1909
Study 24176448 — intervention group
Group type: COMPARATOR
Intervention: LVEDP
Number of subjects: 1909
Study 21873668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein supplementation
Number of subjects: 126
Study 21873668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 19155155 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive patient-oriented group program
Number of subjects: 121
Study 19155155 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based information-only program
Number of subjects: 121
Study 17450074 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate-screw system (n = 20)
Number of subjects: 40
Study 17450074 — intervention group
Group type: EXPERIMENTAL
Intervention: Double rod-screw system (n = 20)
Number of subjects: 40
Study 17450074 — intervention group
Group type: COMPARATOR
Intervention: Both systems (Plate-screw and Double rod-screw)
Number of subjects: 40
Study 15125809 — intervention group
Group type: EXPERIMENTAL
Intervention: AR focus
Number of subjects: 455
Study 15125809 — intervention group
Group type: COMPARATOR
Intervention: No AR focus (Control)
Number of subjects: 455
Study 11417951 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line HDF thrice weekly
Number of subjects: 111
Study 11417951 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line HDF twice weekly
Number of subjects: 111
Study 11417951 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line HDF once weekly
Number of subjects: 111
Study 11417951 — intervention group
Group type: COMPARATOR
Intervention: High-flux HD
Number of subjects: 111
Study 9659029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2 g)
Number of subjects: 120
Study 9659029 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 120
Study 9659029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger plus Droperidol
Number of subjects: 120
Study 9659029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7544967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin cream
Number of subjects: 99
Study 7544967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream
Number of subjects: 99
Study 7544967 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 99
Study 2660996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (200 IU per day)
Number of subjects: 18
Study 2660996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 238046 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Number of subjects: 72
Study 238046 — intervention group
Group type: COMPARATOR
Intervention: chloramphenicol
Number of subjects: 72
Study 30614328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast fetal growth trajectory
Number of subjects: 781
Study 30614328 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-fast fetal growth trajectory
Number of subjects: 781
Study 30614328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest growth trajectory
Number of subjects: 781
Study 30614328 — intervention group
Group type: COMPARATOR
Intervention: Slow fetal growth trajectory
Number of subjects: 781
Study 31291330 — intervention group
Group type: EXPERIMENTAL
Intervention: WAVES intervention (multi-faceted school-based obesity prevention intervention)
Number of subjects: 54
Study 31291330 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 54
Study 27932067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks
Number of subjects: 78
Study 27932067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
Number of subjects: 78
Study 25987092 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care service (nursing care service through hospital and home visits at 1st and 12th weeks)
Number of subjects: 70
Study 25987092 — intervention group
Group type: COMPARATOR
Intervention: Control group (monitored without intervention through hospital routine protocols at 1st and 12th weeks)
Number of subjects: 70
Study 24099813 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg oral once daily
Number of subjects: 56
Study 24099813 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 100 mg oral once daily
Number of subjects: 56
Study 21636711 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative systemic multiagent chemotherapy and intraventricular methotrexate (3 cycles, with possible additional 2 cycles if in complete remission)
Number of subjects: 45
Study 19146568 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIP intervention
Number of subjects: 0
Study 17195765 — intervention group
Group type: EXPERIMENTAL
Intervention: 62% ethyl alcohol in emollient gel
Number of subjects: 39
Study 17195765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% benzalkonium chloride on a sanitary wipe
Number of subjects: 39
Study 17195765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% benzalkonium chloride on a sanitary wipe
Number of subjects: 39
Study 15592697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy
Number of subjects: 53
Study 15592697 — intervention group
Group type: COMPARATOR
Intervention: Low-dose-rate (LDR) brachytherapy
Number of subjects: 53
Study 11701296 — intervention group
Group type: EXPERIMENTAL
Intervention: computer‐generated telephone messages (autodialer)
Number of subjects: 3050
Study 11701296 — intervention group
Group type: EXPERIMENTAL
Intervention: outreach worker
Number of subjects: 3050
Study 11701296 — intervention group
Group type: EXPERIMENTAL
Intervention: autodialer with outreach worker backup
Number of subjects: 3050
Study 11701296 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 3050
Study 9162622 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalant glucocorticoid treatment (IGC)
Number of subjects: 161
Study 9162622 — intervention group
Group type: COMPARATOR
Intervention: Systemic glucocorticoid treatment (SGC)
Number of subjects: 161
Study 7955291 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 1000 IP LVAD with no anticoagulants
Number of subjects: 57
Study 7955291 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 1000 IP LVAD with heparin
Number of subjects: 57
Study 7955291 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 1000 IP LVAD with low‐molecular‐weight dextran
Number of subjects: 57
Study 7955291 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 1000 IP LVAD with dipyridamole plus aspirin
Number of subjects: 57
Study 7955291 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 1000 IP LVAD with miscellaneous agents
Number of subjects: 57
Study 3042938 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated microsphere preparation (Pancrease)
Number of subjects: 0
Study 3042938 — intervention group
Group type: COMPARATOR
Intervention: Conventional pancreatin
Number of subjects: 0
Study 3042938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrease (given for at least 3 months)
Number of subjects: 0
Study 3042938 — intervention group
Group type: COMPARATOR
Intervention: Conventional pancreatin (given 10 months to 8 years earlier)
Number of subjects: 0
Study 31800931 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) for six months
Number of subjects: 166
Study 31800931 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 166
Study 28418398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 26
Study 28418398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26508194 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary procedure combining 2.5% lidocaine and 2.5% prilocaine cream with preparation, education, positioning, and distraction
Number of subjects: 132
Study 26508194 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary procedure
Number of subjects: 132
Study 22738166 — intervention group
Group type: EXPERIMENTAL
Intervention: Multizone refractive multifocal contact lenses
Number of subjects: 30
Study 21943616 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Technique Myofascial Release (DT-MFR)
Number of subjects: 63
Study 21943616 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect Technique Myofascial Release (IDT-MFR)
Number of subjects: 63
Study 21943616 — intervention group
Group type: COMPARATOR
Intervention: Control (slow soft stroking)
Number of subjects: 63
Study 18082664 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estrogen for 7 days during the hormone-free interval
Number of subjects: 0
Study 18082664 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days during the hormone-free interval
Number of subjects: 0
Study 17349080 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN group received encapsulated bacteria (1 x 10(10) CFU of Lactobacillus rhamnosus GG and 1 x 10(10) CFU of Bifidobacterium lactis Bb12) and 10 g of inulin enriched with oligofructose
Number of subjects: 74
Study 17349080 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN treatment in cancer group
Number of subjects: 74
Study 17349080 — intervention group
Group type: COMPARATOR
Intervention: Control group received encapsulated maltodextrin and 10 g of maltodextrin
Number of subjects: 74
Study 15058367 — intervention group
Group type: EXPERIMENTAL
Intervention: experimental toothpaste formulation
Number of subjects: 24
Study 15058367 — intervention group
Group type: COMPARATOR
Intervention: whitening toothpaste product
Number of subjects: 24
Study 15058367 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 24
Study 11316655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 11
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 4314
Study 9396883 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 4314
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 4314
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 4314
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 4314
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical center
Number of subjects: 4314
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4314
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-white race (African-American and other)
Number of subjects: 4314
Study 9396883 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose screen
Number of subjects: 4314
Study 7911290 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 9
Study 3314317 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 15
Study 3314317 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 15
Study 29962359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 216
Study 29962359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 27283216 — intervention group
Group type: EXPERIMENTAL
Intervention: ARVUS technique
Number of subjects: 66
Study 27283216 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior reconstruction
Number of subjects: 66
Study 26264399 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (twice daily)
Number of subjects: 46
Study 26264399 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (daily)
Number of subjects: 46
Study 24333184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Ribavirin (RBV)
Number of subjects: 0
Study 24333184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PegIFN) and Ribavirin (RBV)
Number of subjects: 0
Study 24333184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21059395 — intervention group
Group type: EXPERIMENTAL
Intervention: pCEsa1 DNA vaccine
Number of subjects: 0
Study 21059395 — intervention group
Group type: COMPARATOR
Intervention: Control fish
Number of subjects: 0
Study 18637642 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 0
Study 18637642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17706489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.3 mg/kg bd for 5 days, 0.2 mg/kg bd for 5 days, 0.1 mg/kg bd for 5 days) + Ursodeoxycholic acid (5 mg/kg bd) + Phenobarbitone (5 mg/kg nocte)
Number of subjects: 60
Study 17706489 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 60
Study 17706489 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcome
Number of subjects: 60
Study 17706489 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment
Number of subjects: 60
Study 17706489 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications
Number of subjects: 60
Study 17706489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60
Study 17706489 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative complications
Number of subjects: 60
Study 15379838 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support counselling
Number of subjects: 66
Study 11275389 — intervention group
Group type: EXPERIMENTAL
Intervention: Back pain
Number of subjects: 205
Study 11275389 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom limb pain
Number of subjects: 205
Study 11275389 — intervention group
Group type: EXPERIMENTAL
Intervention: General pain
Number of subjects: 205
Study 9715761 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily for 4 weeks)
Number of subjects: 11
Study 7873290 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 1000 micrograms/day (500 micrograms twice daily) as the sole corticosteroid therapy
Number of subjects: 38
Study 7873290 — intervention group
Group type: COMPARATOR
Intervention: Control group of voluntary healthy non-smoking women
Number of subjects: 38
Study 3322749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium excision with Sr 90 irradiation
Number of subjects: 51
Study 3322749 — intervention group
Group type: COMPARATOR
Intervention: Bare sclera technique alone (control)
Number of subjects: 51
Study 3322749 — intervention group
Group type: EXPERIMENTAL
Intervention: More complicated pterygium operations (including conjunctival flaps and keratoplasty)
Number of subjects: 51
Study 31863563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1533
Study 31863563 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 1533
Study 30125345 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with PCA
Number of subjects: 42
Study 30125345 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with epidural
Number of subjects: 42
Study 30125345 — intervention group
Group type: COMPARATOR
Intervention: Patients with preoperative insulin resistance (IR)
Number of subjects: 42
Study 30125345 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal insulin sensitivity (IS)
Number of subjects: 42
Study 28573681 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 0
Study 28573681 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 0
Study 25761658 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional beverage (FB) based on grape skin polyphenols, single-dose intake (187 mL)
Number of subjects: 31
Study 25761658 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional beverage (FB) based on grape skin polyphenols, sustained consumption (twice per day, 187 mL per day for 15 days)
Number of subjects: 31
Study 25761658 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional beverage (FB) based on grape skin polyphenols, both acute and sustained consumption
Number of subjects: 31
Study 23481448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of trivalent inactivated influenza vaccine
Number of subjects: 22
Study 23481448 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of trivalent inactivated influenza vaccine
Number of subjects: 22
Study 21238826 — intervention group
Group type: EXPERIMENTAL
Intervention: Punch biopsy specimens
Number of subjects: 73
Study 19473594 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 20 mg/kg
Number of subjects: 182
Study 19473594 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 40 mg/kg
Number of subjects: 182
Study 19473594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 19473594 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 182
Study 17316692 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback cue delivered through ear phones (device on)
Number of subjects: 14
Study 17316692 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback cue delivered through ear phones (residual effects)
Number of subjects: 14
Study 17316692 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 14
Study 15054409 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exercise (cycling for 1 hour at 70-75% of maximal heart rate)
Number of subjects: 9
Study 15054409 — intervention group
Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 9
Study 10833065 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AO) supplementation
Number of subjects: 25
Study 10833065 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 fatty acids plus antioxidants (AO) supplementation
Number of subjects: 25
Study 10833065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9221486 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg human calcitonin (hCT)
Number of subjects: 6
Study 9221486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1441864 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg rectally 12 h and 1 h before surgery and 20 mg 24 h postoperatively
Number of subjects: 28
Study 1441864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1441864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Piroxicam and Placebo)
Number of subjects: 28
Study 3516580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fenoverine 3-times daily for 20 days
Number of subjects: 40
Study 3516580 — intervention group
Group type: COMPARATOR
Intervention: 150 mg trimebutine 3-times daily for 20 days
Number of subjects: 40
Study 3516580 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoverine
Number of subjects: 40
Study 3516580 — intervention group
Group type: COMPARATOR
Intervention: trimebutine
Number of subjects: 40
Study 3516580 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoverine and trimebutine
Number of subjects: 40
Study 27031649 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST) with laparoscopic cholecystectomy (LC)
Number of subjects: 51
Study 27031649 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic common bile duct exploration during LC
Number of subjects: 51
Study 24472002 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week stenting (1W series)
Number of subjects: 100
Study 24472002 — intervention group
Group type: COMPARATOR
Intervention: 4-week stenting (4W series)
Number of subjects: 100
Study 22882579 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mixed-dilution OL-HDF
Number of subjects: 12
Study 22882579 — intervention group
Group type: COMPARATOR
Intervention: Simple mid-dilution OL-HDF
Number of subjects: 12
Study 21054971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis multifocal aspheric IOL (Tecnis ZM900, AMO)
Number of subjects: 100
Study 21054971 — intervention group
Group type: COMPARATOR
Intervention: Monofocal spherical IOL (Akreos Adapt, Bausch & Lomb)
Number of subjects: 100
Study 18936645 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI < 30 kg/m2
Number of subjects: 964
Study 18936645 — intervention group
Group type: COMPARATOR
Intervention: BMI >= 30 kg/m2
Number of subjects: 964
Study 15805196 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip arthroplasty (short incision <or=10 cm)
Number of subjects: 219
Study 15805196 — intervention group
Group type: COMPARATOR
Intervention: Standard incision total hip arthroplasty (16 cm)
Number of subjects: 219
Study 12879670 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg.kg-1 bolus followed by a continuous infusion of 12 mg.kg-1.h-1)
Number of subjects: 93
Study 12879670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 93
Study 11008847 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making training addressing both cognitive and motivational aspects
Number of subjects: 36
Study 11008847 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making training including only cognitive aspects
Number of subjects: 36
Study 11008847 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 8838779 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex) at a starting dose of 40 mg/day, increased by 40 mg/day every 6 weeks until target dose achieved.
Number of subjects: 0
Study 8838779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 1383958 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial synchronous pacing (DDD)
Number of subjects: 17
Study 1383958 — intervention group
Group type: COMPARATOR
Intervention: Rate modulated ventricular pacing (VVI,R)
Number of subjects: 17
Study 2998802 — intervention group
Group type: EXPERIMENTAL
Intervention: co-dergocrine (Hydergine)
Number of subjects: 20